Glioma and other CNS tumors: cross-border specialty drug access for international patients

Quick orientation

Primary brain and CNS tumors account for approximately 1 to 2 percent of all cancers globally. Gliomas including glioblastoma are the most common primary malignant brain tumors in adults.

Typical age of onset. All ages; specific subtypes have characteristic age distributions. Pediatric gliomas are biologically distinct from adult disease.

Severity tiers. Severity depends on grade, molecular subtype, and location. Glioblastoma carries a particularly poor prognosis.

Why specialty drugs for Glioma and other CNS tumors are hard to access internationally

IDH-targeted, BRAF/MEK, and other molecularly-targeted therapies for specific glioma subtypes are recent additions to the armamentarium. Many are not yet registered in MENA, South Asia, or Latin America, where access to molecular profiling is also uneven.

Treatments approved by the FDA

• Voranigo (vorasidenib) — FDA approval: 2024. Mechanism: Dual IDH1/IDH2 inhibitor for low-grade IDH-mutant glioma. Route: Oral once daily. US WAC ballpark: Approximately USD 380,000 per year. Country pricing: UAE · Qatar.
• Ojemda (tovorafenib) — FDA approval: 2024. Mechanism: Type II RAF inhibitor for pediatric low-grade glioma with BRAF alterations. Route: Oral once weekly. US WAC ballpark: Approximately USD 350,000 per year, weight-based. Country pricing: UAE · Saudi Arabia · India · Egypt.
• Modeyso (dordaviprone) — FDA approval: 2025. Mechanism: Imipridone for H3 K27M-mutant diffuse glioma. Route: Oral. US WAC ballpark: Approximately USD 380,000 per year. Country pricing: Saudi Arabia · Egypt · Jordan · Bahrain · Lebanon.

Cross-border pathways used for Glioma and other CNS tumors

Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:

• Named Patient Program (NPP)
• Expanded Access Program (EAP)
• Compassionate Use
• Personal Import Scheme

What your physician needs to know

• Confirm molecular subtype (IDH status, BRAF, H3K27M, MGMT methylation).
• Document prior treatment and progression status.
• Coordinate with neuro-oncology center; some products require specialist co-management.
• Monitor liver function and other label-specific labs.
• Pediatric cases require pediatric neuro-oncology input.

Common questions

How does molecular profiling fit in?

Targeted therapy choice depends on molecular markers. Where local profiling is unavailable, we can coordinate sample referral to qualified labs.

Are these drugs approved in my country?

Registration varies. We confirm by destination.

Can a pediatric patient receive Ojemda?

Yes, the FDA label is pediatric for BRAF-altered low-grade glioma.

How long does shipment take?

Five to fifteen business days from prescription receipt.

What documents are required?

Oncologist's prescription, pathology report including molecular profile, imaging, and clinical summary.

Where Reserve Meds fits in

Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For Glioma and other CNS tumors, our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.

We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.

Start a request

Request a drug for Glioma and other CNS tumors

Reserved for you.